A novel – and rapid – anti-cancer drug development strategy has resulted in a new drug that stops kidney and pancreatic（胰腺） tumors from growing in mice. Researchers at the Moores Cancer Center at the University of California, San Diego, have found a drug that binds² to a molecular³ "switch" found in cancer cells and cancer-associated blood vessels⁵ to keep it in the "off" position. "We locked the kinase（激酶，致活酶） switch in the off position in cancer and in tumor¹-associated blood vessels," which differs from the way current inhibitors（禁制因素，抑制因子） attempt to block active kinases, said David Cheresh, PhD, professor and vice⁶ chair of pathology（病理学） at the UCSD School of Medicine and the Moores UCSD Cancer Center, who led the work.

The new approach employs scaffold-based chemistry combined with supercomputer technology, allowing for rapid screening and development of drugs that are more selective for the tumor. The development and screening processes were used to identify potential drug candidates able to halt a growth signaling enzyme⁷（酶） , or kinase, which can foster（养育，抚育） tumor blood vessel⁴ and tumor growth. According to the researchers, the novel approach may become a useful strategy in cancer drug development. The study appears online the week of February 8, 2010, in the Proceedings⁸ of the National Academy of Sciences.

In this "rational design approach," Cheresh and his co-workers used the supercomputer at the San Diego Supercomputer Center to custom-design molecules⁹ that stabilized¹⁰ the inactive forms of two similar kinases, PDGFRβ and B-RAF – both of which are found to be activated¹¹ in tumors and in blood vessels that feed tumors. Since PDGFRβ and B-RAF work cooperatively, keeping both turned off causes synergistic effects（协同效应） in tumors, according to Cheresh.

"We custom design a drug for a target that we know either plays a role in blood vessel angiogenesis（血管生成） or tumor invasion," said Cheresh. "By doing this on the computer screen and effectively locking the target in the off position, we can generate selective drugs that are expected to produce minimal¹² side effects（副作用） . Working with a series of chemical scaffolds（脚手架，支架） , we are able to design specific interactions to fit certain targets in cancer cells."

They tested candidates for their effects on embryonic¹³（胚胎的） zebrafish blood vessels, which behave similarly to human cancer blood vessels. Molecules that blocked blood vessel growth in the fish were found to do the same in mice, and Cheresh hopes they will soon be tested in cancer patients.

The drug screen system has several advantages, Cheresh explained. Most standard screens test 400,000 candidates in test tubes to identify a single drug candidate. His group's screening method requires fewer than 100 compounds to be screened because they are rationally designed, look for specific types of targets, and use a zebrafish model, testing molecules in cells, tissues and organs for "physiological¹⁴ relevance¹⁵." The zebrafish is a popular drug research model because it is transparent¹⁶ and the effects of drugs are easily monitored.

In addition, he said, the rational design（合理的设计） approach provides drugs that are more selective, hitting desired targets and yielding fewer side effects.